By Athena Mandros

Last week we covered the “rules” of the 340B Drug Discount Program (340B Program), which requires drug manufacturers to provide discounts on outpatient drugs to certain types of provider organizations in order to participate in the Medicaid program (see The Market Advantage Of the 340B Program). The program is viewed as “essential” by the executives of many safety net provider organizations – both for their consumers and to minimize lost revenue on pharmacy services for the uninsured. Currently, there are some proposed changes to the 340B Program in wings. In January 2015, the Medicare Payment Advisory Commission (MedPAC) voted 14-3…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!